Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M.M. Eggermont, Ulrich Keilholz, Stefan Suciu et al.|The Lancet|2008Cited by 642
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Rahima Jamal et al.|The Lancet Oncology|2021Cited by 389
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialAlexander M.M. Eggermont, Danielle Líénard, Stefan Suciu et al.|The Lancet|2005Cited by 314
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma studyLeila Khoja, Anthony M. Joshua, Eshetu G. Atenafu et al.|Annals of Oncology|2019Cited by 282
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III MelanomaAlexander M.M. Eggermont, Ulrich Keilholz, Stefan Suciu et al.|Journal of Clinical Oncology|2012Cited by 281